Amicus Therapeutics, Inc. (LON:0HF9)
9.18
-0.09 (-0.93%)
At close: Feb 21, 2025
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $141.52M USD in the quarter ending September 30, 2024, with 36.73% growth. This brings the company's revenue in the last twelve months to $493.67M, up 32.58% year-over-year. In the year 2023, Amicus Therapeutics had annual revenue of $399.36M with 21.30% growth.
Revenue (ttm)
$493.67M
Revenue Growth
+32.58%
P/S Ratio
n/a
Revenue / Employee
$954.88K
Employees
517
Market Cap
2.18B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |
Amicus Therapeutics News
- 3 days ago - Amicus Therapeutics files for potential mixed shelf offering - Seeking Alpha
- 3 days ago - SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Business Wire
- 3 days ago - Amicus Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Amicus Therapeutics Inc (FOLD) Reports Q4 Revenue of $149.7M, Surpassing Estimates of $148.01M - GuruFocus
- 4 days ago - Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 4 days ago - Amicus Therapeutics FY 2024 Earnings Preview - Seeking Alpha
- 5 days ago - Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm - GlobeNewsWire